Accelerating Clinical Translation of Antibody-Drug Conjugates with Hybrid AI

Bringing a new drug to market costs far too much and takes far too long — and for cancer treatments especially, there is inherent urgency around getting these life-saving medications to patients faster. Antibody-drug conjugates show tremendous promise as a more selective therapy modality. But, as the industry investigates more conjugates and payload combinations, the expansion of preclinical research and experimentation is exploding.

Can adding artificial intelligence (AI) to the drug discovery and development process help manage the combinatory scale challenge posed by antibody-drug conjugates? Are all AI approaches the same? What challenges will teams face and how can they be overcome when adopting different AI approaches to their research and development plans? What can drug developers realistically expect in terms of worthwhile outcomes?

In this webinar, the expert speakers will discuss how VeriSIM Life and Debiopharm partnered to scalably investigate first-in-human (FIH) dosing strategies for antibody-drug conjugates to reduce tumor burden safely and effectively. Topics explored will include:

• How AI tangibly impacts preclinical research, specifically for the development of antibody-drug conjugate therapies in this instance
• What benefits of an in vivo experimentation strategy can be realized by bringing in AI
• Challenges faced when trying to integrate many complex insights such as drug exposure, in vivo efficacy, toxicity thresholds and more
• How to develop a systematic approach to integrate these insights in dose selection for humans

The speakers will also share details right from the first step of evaluating a technology partner to the implementation of the solution and the results.

Register for this webinar to discover the transformative role of AI in accelerating antibody-drug conjugate development for cancer treatment.

Speakers

Dr. Jo Varshney, PhD, DVM, CEO, VeriSIM Life

Dr. Jo Varshney is the Founder and CEO of VeriSIM Life and President and CEO of PulmoSIM Therapeutics, which is a subsidiary of VeriSIM Life. She is the inventor of VeriSIM Life’s BIOiSIM core technology. Dr. Varshney is a Doctor in Veterinary Medicine (DVM) and holds a PhD in Comparative Oncology/Genomics from the University of Minnesota, as well as graduate degrees in Comparative Pathology from Penn State and Computational Sciences from UC San Francisco. Dr. Varshney’s commentary on the use of technology to improve the translation of novel therapies to successful clinical outcomes has been featured in trade publications, national media and scientific journals. Additionally, she serves on several advisory boards as scientific/technical advisor, including the Critical Path Institute (C-Path), to further novel platforms to foster a technology ecosystem for enabling broader access to disease progression models and clinical trial simulation applications.

Message Presenter

Dr. Annick Menetrey, PhD, Clinical Pharmacology Lead, Debiopharm

Dr. Annick Menetrey, PhD, is Clinical Pharmacology Lead in the Translational Medicine Department at Debiopharm, a biopharmaceutical company based in Switzerland. She brings to her role a wealth of expertise in both clinical and nonclinical drug development, with over 20 years working in R&D across various therapeutic areas. Her primary focus lies within infectious diseases and oncology. Dr. Annick obtained her PhD in Life Sciences from the University of Lausanne in 2004 and further expanded her knowledge with additional certification from the Lemanic Network of Toxicology. In her current role at Debiopharm, she collaborates with multidisciplinary teams to support the clinical development of oncology drug products, including small molecules and biologics. She is particularly interested in innovative methodologies that accelerate clinical pharmacology understanding such as modeling and simulation techniques for more informed decision-making during drug development.

Message Presenter